Botanix PharmaceuticalsBXPHF +14.04% PS Ratio is 1.63 as of Jul. 12, 2026, which is 96% below its 10-year median of 40.00. The stock has 7 warning signs investors should review. Among 930 Biotechnology companies, Botanix Pharmaceuticals ranks better than 83.76% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Botanix Pharmaceuticals's share price is $0.013.
Botanix Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01. Hence, Botanix Pharmaceuticals's PS Ratio for today is 1.63.
The historical rank and industry rank for Botanix Pharmaceuticals's PS Ratio or its related term are showing as below:
BXPHF'
s PS Ratio Range Over the Past 10 Years
Min: 2.18 Med: 40 Max: 113.33
Current: 2.18
During the past 13 years, Botanix Pharmaceuticals's highest PS Ratio was 113.33. The lowest was 2.18. And the median was 40.00.
BXPHF's PS Ratio is ranked better than 83.76% of 930
companies
in the Biotechnology industry
Industry Median: 9.51
vs BXPHF: 2.18
Botanix Pharmaceuticals (OTCPK:BXPHF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Botanix Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Botanix Pharmaceuticals PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Botanix Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where Botanix Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Botanix Pharmaceuticals's Share Price of today is $0.013.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Botanix Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Botanix Pharmaceuticals (BXPHF) has a PS Ratio of 1.63 as of Jul. 12, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Botanix Pharmaceuticals and its competitors. This is 96% below median its historical median of 40.00. Over the past decade, Botanix Pharmaceuticals' PS Ratio has ranged from 2.18 to 113.33. According to the industry distribution chart, Botanix Pharmaceuticals ranks #151 out of 930 companies in the Biotechnology industry, placing it in the top 16.2%.
Is Botanix Pharmaceuticals' PS Ratio too high?
Botanix Pharmaceuticals' current PS Ratio of 1.63 is 96% below median its 10-year median of 40.00. Over the past 10 years, this metric has ranged from a low of 2.18 to a high of 113.33. The Biotechnology industry median PS Ratio is 9.51. Botanix Pharmaceuticals' value of 1.63 is 82.9% below this industry median. Based on the distribution chart, Botanix Pharmaceuticals ranks #151 out of 930 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Botanix Pharmaceuticals' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Botanix Pharmaceuticals ranks #151 out of 930 companies for PS Ratio. This places Botanix Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.51. Botanix Pharmaceuticals' value of 1.63 is 82.9% below this benchmark. Historically, Botanix Pharmaceuticals' own PS Ratio has ranged from 2.18 to 113.33 over the past decade. While the company's 10-year median is 40.00 vs. the industry median of 9.51, Botanix Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.51, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Botanix Pharmaceuticals's current PS Ratio of 1.63 is 82.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Botanix Pharmaceuticals and its competitors. For the Biotechnology industry, the median PS Ratio is 9.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Botanix Pharmaceuticals's current PS Ratio is 1.63, which is 96% below median its own 10-year median of 40.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Botanix Pharmaceuticals stock overvalued right now?
Botanix Pharmaceuticals (BXPHF) has a current PS Ratio of 1.63. The current PS Ratio is 1.63, which is 96% below median its 10-year median of 40.00 and 82.9% below the Biotechnology industry median of 9.51. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Botanix Pharmaceuticals (BXPHF), the current PS Ratio is 1.63 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system for all skin diseases. The company's product pipeline includes BTX 1503 - Moderate to Severe Acne, BTX 1204 - Atopic Dermatitis, BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is derived from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BXPHF has been successfully added to your 